Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure
暂无分享,去创建一个
[1] S. Libutti,et al. Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors , 2018, Journal of the National Cancer Institute.
[2] Ruud P. M. Dings,et al. Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-α and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models. , 2015, International journal of radiation oncology, biology, physics.
[3] Xinbing Sui,et al. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients , 2015, Oncotarget.
[4] K. Shiraishi,et al. Interstitial Fluid Pressure Correlates Clinicopathological Factors of Lung Cancer. , 2015, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.
[5] Lawrence Tamarkin,et al. Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine , 2010, Clinical Cancer Research.
[6] Nicholas Denko,et al. Overcoming Physiologic Barriers to Cancer Treatment by Molecularly Targeting the Tumor Microenvironment , 2006, Molecular Cancer Research.
[7] Michael Stumm,et al. Patupilone Induced Vascular Disruption in Orthotopic Rodent Tumor Models Detected by Magnetic Resonance Imaging and Interstitial Fluid Pressure , 2005, Clinical Cancer Research.
[8] Kristian Pietras,et al. High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.
[9] John N Weinstein,et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.